Peter Kolb

Scientific Advisory Board Member at Confo Therapeutics

Peter is a Professor of Pharmaceutical Chemistry, funded by the Heisenberg program of the German Research Foundation DFG, at Philipps-University (Marburg, Germany). He is an expert in fragment-based and structure-based ligand design for GPCRs and enzymes, focusing predominantly on computational approaches.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Confo Therapeutics

1 followers

Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.


Industries

Headquarters

Elsene, Belgium

Employees

11-50

Links